Evidence map›Paper›PMID 39252620›Full record

ReviewCurrent medicinal chemistry2025

Role and Therapeutic Potential of P2X7 Receptor in Lung Cancer Progression.

Yahui Cao, Yanan Du, Wei Song, Qingqing Yu, Xin Wang, Ronglan Zhao, Xiaoxiang Peng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yahui CaoSchool of Medical Laboratory, Shandong Second Medical University, Weifang, Shandong, 261053, China.
Yanan DuSchool of Medical Laboratory, Shandong Second Medical University, Weifang, Shandong, 261053, China.
Wei SongSchool of Medical Laboratory, Shandong Second Medical University, Weifang, Shandong, 261053, China.
Qingqing YuSchool of Medical Laboratory, Shandong Second Medical University, Weifang, Shandong, 261053, China.
Xin WangSchool of Medical Laboratory, Shandong Second Medical University, Weifang, Shandong, 261053, China.
Ronglan ZhaoSchool of Medical Laboratory, Shandong Second Medical University, Weifang, Shandong, 261053, China.
Xiaoxiang PengSchool of Medical Laboratory, Shandong Second Medical University, Weifang, Shandong, 261053, China.

Funding

National Natural Science Foundation of China 81770915Shandong Provincial Natural Science Foundation ZR2023MH307, ZR2021MH306
6 · The paper itself

Abstract

Lung cancer is the second malignant tumor in the world and is the most prevalent malignant tumor of the respiratory system. In lung cancer, the P2X7 receptor (P2X7R) is an important purinergic receptor. P2X7R is a class of ionotropic adenosine triphosphate (ATP)-gated receptors, which exists in many kinds of immune tissues and cells and is involved in tumorigenesis and progression. P2X7R is closely related to lung cancer and is expressed at higher levels in lung cancer than in normal lung tissue. P2X7R plays a critical regulatory function in lung cancer invasion and migration through multiple mechanisms of action and affects the proliferation and apoptosis of cancer cells in the lung. Antagonists of P2X7R can block its function, which in turn has a significant inhibitory effect on lung cancer cell development and progression. This paper details a comprehensive overview of the structure and function of P2X7R. It focuses on the impact and treatment potential of P2X7R in lung cancer invasion, migration, proliferation, and apoptosis, providing new ideas and a new basis for clinical lung cancer treatment and prognosis.

Indexed as

Antineoplastic AgentsLung NeoplasmsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7AnimalsApoptosisCell MovementCell ProliferationDisease ProgressionHumansAntineoplastic AgentsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X7apoptosis.ATPinvasionlung cancermigrationP2X7RP2X7R antagonistproliferation

Identifiers

PMID39252620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.